Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly

被引：32

作者：

Betsch, A. ^{[1
]}

Rutgeerts, O. ^{[2
]}

Fevery, S. ^{[2
]}

Sprangers, B. ^{[2
]}

Verhoef, G. ^{[1
]}

Dierickx, D. ^{[1
]}

Beckers, M. ^{[1
]}

机构：

[1] Univ Leuven, KU Leuven, Lab Expt Hematol, Dept Oncol,Univ Hosp Leuven,Dept Hematol, B-3000 Leuven, Belgium

[2] Univ Leuven, KU Leuven, Dept Microbiol & Immunol, Lab Expt Transplantat,Univ Hosp Leuven,Dept Nephr, B-3000 Leuven, Belgium

来源：

BLOOD REVIEWS | 2018年 / 32卷 / 06期

关键词：

MDSC; Lymphoma; Immunotherapy; BRUTONS TYROSINE KINASE; T-CELLS; IMMUNE SUPPRESSION; TUMOR PROGRESSION; MULTIPLE-MYELOMA; IMMUNOSUPPRESSIVE ACTIVITY; PROGNOSTIC-SIGNIFICANCE; HODGKIN LYMPHOMA; CANCER; EXPANSION;

D O I：

10.1016/j.blre.2018.04.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lymphomas cause significant morbidity and mortality worldwide.. A substantial number of patients ultimately relapse after standard treatment. However, the efficacy of these therapies can be counteracted by the patients' immune system, more specifically by myeloid-derived suppressor cells (MDSC). MDSC are a heterogeneous group of immature myeloid cells that suppress the innate and adaptive immune system via different mechanisms and accumulate under pathological conditions, such as cancer. MDSC play a role in the induction and progression of cancer and immune evasion. Increased numbers of MDSC have been reported in different lymphoma subtypes and are associated with a poor clinical outcome. This review aims to clarify the role of MDSC and their working mechanism in different lymphoma subtypes. Furthermore, the effect of MDSC on immunotherapies will be discussed.

引用

页码：490 / 498

页数：9

共 97 条

[1] Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer [J].

Ali, Khaled ;

Soond, Dalya R. ;

Pineiro, Roberto ;

Hagemann, Thorsten ;

Pearce, Wayne ;

Lim, Ee Lyn ;

Bouabe, Hicham ;

Scudamore, Cheryl L. ;

Hancox, Timothy ;

Maecker, Heather ;

Friedman, Lori ;

Turner, Martin ;

Okkenhaug, Klaus ;

Vanhaesebroeck, Bart .

NATURE, 2014, 510 (7505) :407-+

[2]

[Anonymous], 2014, BLOOD

[3]

[Anonymous], BLOOD

[4]

[Anonymous], BLOOD

[5]

[Anonymous], LEUK LYMPHOMA

[6] Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].

Ansell, Stephen M. ;

Hurvitz, Sara A. ;

Koenig, Patricia A. ;

LaPlant, Betsy R. ;

Kabat, Brian F. ;

Fernando, Donna ;

Habermann, Thomas M. ;

Inwards, David J. ;

Verma, Meena ;

Yamada, Reiko ;

Erlichman, Charles ;

Lowy, Israel ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453

[7] Non-Hodgkin lymphoma [J].

Armitage, James O. ;

Gascoyne, Randy D. ;

Lunning, Matthew A. ;

Cavalli, Franco .

LANCET, 2017, 390 (10091) :298-310

[8] T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells [J].

Azzaoui, Imane ;

Uhel, Fabrice ;

Rossille, Delphine ;

Pangault, Celine ;

Dulong, Joelle ;

Le Priol, Jerome ;

Lamy, Thierry ;

Houot, Roch ;

Le Gouill, Steven ;

Cartron, Guillaume ;

Godmer, Pascal ;

Bouabdallah, Krimo ;

Milpied, Noel ;

Damaj, Gandhi ;

Tarte, Karin ;

Fest, Thierry ;

Roussel, Mikael .

BLOOD, 2016, 128 (08) :1081-1092

[9]

Bauer K, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007941.pub2, 10.1002/14651858.CD007941]

[10]

BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →